Tower Research Capital (TRC)’s Filana Therapeutics FLNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.51K | Sell |
2,076
-2,842
| -58% | -$5.85K | ﹤0.01% | 4307 |
|
|
2025
Q4 | $9.74K | Sell |
4,918
-505
| -9% | -$1.62K | ﹤0.01% | 3876 |
|
|
2025
Q3 | $15.8K | Sell |
5,423
-7,606
| -58% | -$17.5K | ﹤0.01% | 3522 |
|
|
2025
Q2 | $23.6K | Buy |
13,029
+6,467
| +99% | +$11.5K | ﹤0.01% | 3588 |
|
|
2025
Q1 | $9.84K | Buy |
6,562
+15
| +0.2% | +$38 | ﹤0.01% | 3715 |
|
|
2024
Q4 | $15.5K | Buy |
6,547
+336
| +5% | +$5.9K | ﹤0.01% | 3406 |
|
|
2024
Q3 | $183K | Sell |
6,211
-5,850
| -49% | -$135K | ﹤0.01% | 1711 |
|
|
2024
Q2 | $149K | Buy |
12,061
+11,033
| +1,073% | +$233K | ﹤0.01% | 2300 |
|
|
2024
Q1 | $20.9K | Sell |
1,028
-7,470
| -88% | -$172K | ﹤0.01% | 2965 |
|
|
2023
Q4 | $191K | Buy |
8,498
+6,603
| +348% | +$139K | ﹤0.01% | 2135 |
|
|
2023
Q3 | $31.5K | Sell |
1,895
-1,080
| -36% | -$21.4K | ﹤0.01% | 2979 |
|
|
2023
Q2 | $72.9K | Sell |
2,975
-2,458
| -45% | -$59.2K | ﹤0.01% | 2277 |
|
|
2023
Q1 | $131K | Buy |
5,433
+3,892
| +253% | +$108K | ﹤0.01% | 1633 |
|
|
2022
Q4 | $45K | Buy |
1,541
+187
| +14% | +$6.72K | ﹤0.01% | 2434 |
|
|
2022
Q3 | $56K | Sell |
1,354
-8,553
| -86% | -$231K | ﹤0.01% | 3069 |
|
|
2022
Q2 | $278K | Buy |
9,907
+7,531
| +317% | +$190K | 0.01% | 1539 |
|
|
2022
Q1 | $88K | Buy |
2,376
+425
| +22% | +$18K | ﹤0.01% | 2304 |
|
|
2021
Q4 | $85K | Buy |
1,951
+134
| +7% | +$7.03K | ﹤0.01% | 2341 |
|
|
2021
Q3 | $113K | Sell |
1,817
-5,547
| -75% | -$463K | ﹤0.01% | 2300 |
|
|
2021
Q2 | $629K | Buy |
7,364
+4,849
| +193% | +$260K | 0.02% | 989 |
|
|
2021
Q1 | $113K | Sell |
2,515
-892
| -26% | -$35.1K | ﹤0.01% | 2502 |
|
|
2020
Q4 | $23K | Sell |
3,407
-19,106
| -85% | -$171K | ﹤0.01% | 3782 |
|
|
2020
Q3 | $259K | Buy |
22,513
+21,362
| +1,856% | +$96.3K | ﹤0.01% | 2319 |
|
|
2020
Q2 | $4K | Sell |
1,151
-698
| -38% | -$3.17K | ﹤0.01% | 4360 |
|
|
2020
Q1 | $8K | Buy |
+1,849
| New | +$12.2K | ﹤0.01% | 2126 |
|
|
2017
Q3 | – | Sell |
-79
| Closed | – | – | 4096 |
|
|
2017
Q2 | $0 | Buy |
+79
| New | +$373 | ﹤0.01% | 3357 |
|
|
2017
Q1 | – | Sell |
-1,368
| Closed | -$5K | – | 3800 |
|
|
2016
Q4 | $5K | Buy |
+1,368
| New | +$6.34K | ﹤0.01% | 3060 |
|
|
2016
Q3 | – | Sell |
-3,052
| Closed | -$47K | – | 4330 |
|
|
2016
Q2 | $47K | Buy |
3,052
+2,753
| +921% | +$43.7K | ﹤0.01% | 1595 |
|
|
2016
Q1 | $5K | Sell |
299
-886
| -75% | -$11.5K | ﹤0.01% | 2726 |
|
|
2015
Q4 | $14K | Buy |
+1,185
| New | +$15.7K | ﹤0.01% | 1715 |
|
|
2015
Q3 | – | Sell |
-202
| Closed | -$2K | – | 4655 |
|
|
2015
Q2 | $2K | Buy |
+202
| New | +$2.77K | ﹤0.01% | 3787 |
|
|
2014
Q4 | – | Sell |
-644
| Closed | -$18K | – | 4609 |
|
|
2014
Q3 | $18K | Buy |
644
+629
| +4,193% | +$19.1K | ﹤0.01% | 2393 |
|
|
2014
Q2 | $1K | Sell |
15
-86
| -85% | -$3.18K | ﹤0.01% | 3745 |
|
|
2014
Q1 | $4K | Sell |
101
-1
| -1% | -$35 | ﹤0.01% | 3462 |
|
|
2013
Q4 | $3K | Buy |
+102
| New | +$2.71K | ﹤0.01% | 3868 |
|
|
2013
Q3 | – | Sell |
-1,131
| Closed | -$18K | – | 4795 |
|
|
2013
Q2 | $18K | Buy |
+1,131
| New | +$23.9K | ﹤0.01% | 1820 |
|
Other funds holding FLNA
VCM
GC
Tower Research Capital (TRC)'s FLNA Position: Q1 2026 in Review
Tower Research Capital (TRC) reduced its Filana Therapeutics (FLNA) stake by 58% in Q1 2026, selling an estimated $5.85K and leaving 2,076 shares worth $3.51K. The position accounts for ﹤0.01% of the portfolio, ranked #4307.
Tower Research Capital (TRC) first reported a position in FLNA in Q2 2013 and has held it in 36 quarters since. The position peaked at $629K in Q2 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.
- Tower Research Capital (TRC) held 2,076 shares of Filana Therapeutics worth $3.51K as of Q1 2026.
- Tower Research Capital (TRC) sold 2,842 Filana Therapeutics shares in Q1 2026, an estimated $5.85K.
- Filana Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4307 holding.
- Tower Research Capital (TRC) first reported a position in Filana Therapeutics in Q2 2013 and has held it in 36 quarters since.
- Tower Research Capital (TRC)'s Filana Therapeutics position peaked at $629K in Q2 2021.
- 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.